Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Histopathology. 2015 Jan 12;66(5):627–638. doi: 10.1111/his.12466

Table 5.

Time to first metastasis, univariate analyses

Variable Level N # with metastases Hazard Ratio 95% CI Lower 95% CI upper P- Value
Univariate analyses
Actin, smooth muscle >10% pos 92 51 0.9286 0.1276 6.7582 0.9417
Caldesmon >10% pos 93 52 0.6418 0.288 1.4304 0.2781
Desmin >10% pos 93 52 0.4643 0.2407 0.8957 0.0221
Myosin, smooth muscle >10% pos 91 50 0.8576 0.4156 1.7696 0.6777
Standard muscle markers all 4 markers expressed 90 49 0.5986 0.3255 1.101 0.0988
ACTG2 strong, diffuse 92 51 1.789 0.2462 13.0021 0.5654
CASQ2 strong, diffuse 92 51 0.6913 0.367 1.302 0.253
CFL2 strong, diffuse 87 46 0.559 0.2876 1.0868 0.0864
MYLK strong, diffuse 91 50 0.9674 0.3463 2.7026 0.9496
SLMAP strong, diffuse 93 52 0.8091 0.3794 1.7254 0.5835
Type-1 leiomyosarcoma markers muscle enriched (any 3/5) 90 49 0.8023 0.2872 2.2412 0.6743
differentiation score moderate
poor
93 52 1.104
2.4072
0.6043
0.9684
2.0171
5.9836
0.7476
0.0587
gender (M/F) M 93 52 1.324 0.766 2.2886 0.3148
site (U/S)
Size
Uterine vs all other
>5 cm
93
93
52
52
0.5359
1.7609
0.1927
0.881
1.4903
3.5196
0.2319
0.1093